Idiopathic dilated cardiomyopathy was defined as global ventricular dilatation with impaired systolic fumction in the absence of a known cause. ' In view of the large amount of ongoing research in the field the definition has recently been expanded to say that dilated cardiomyopathy "may be familial/genetic, viral and/or autoimmune, or alcoholic/toxic".2 The most popular causal hypothesis for dilated cardiomyopathy is an autoimmune process initiated by an environmental trigger, for example viral illness, alcohol, or pregnancy. This autoimmune theory has been lent support by an increased frequency of HLA-DR4 and by the presence of circulating cardiac autoantibodies in some patients with dilated cardiomyopathy. 4 The first prospective studies in which relatives of patients with dilated cardiomyopathy were screened were reported recently and gave a familial prevalence of 20-25%.56 Screening could identify latent forms of the disease which may respond better to treatment, with an improvement in prognosis. The To date, 200 first degree relatives from 56 proband families have attended for echocardiography. The disease was considered to be familial if at least one first degree relative was diagnosed as having dilated cardiomyopathy, as defined above. If a first degree relative fulfilled only one of the criteria for the diagnosis of dilated cardiomyopathy-that is, a left ventricular ejection below 50% or a left ventricular end diastolic dimension more than two standard deviations above the mean-they were entered in a "possible" category for further follow up. Any families with a history of premature sudden death (unexplained at an age of less than 50 years) were also included in the "possible" category.
STATISTICS
Differences between proportions of patients and controls, and familial and non-familial patient subgroups, with regard to HLA distribution were compared using the X2 test.
Results

FAMILY SCREENING
A total of 270 first degree relatives from 75 of the 100 patient families were potentially available for screening. Twenty five of the 100 patients either had no family members available for screening or did not wish their relatives to be contacted. So far, 200 of a possible 270 first degree relatives (74%), from 56 of the 75 proband families (75%), have been screened by echocardiography. Those not screened include relatives still to be contacted, non-attenders, and those residing abroad. Of the 56 families screened, five (9%) had a first degree relative already diagnosed as having dilated cardiomyopathy, and a further nine (16%) had at least one relative who fulfilled both echocardiographic criteria for dilated cardiomyopathy. Thus the "definite" familial occurrence of dilated cardiomyopathy in this patient group was 14 of 56 (25%). In a further nine families (16%), one relative had a "possible" diagnosis of dilated cardiomyopathy, that is, only one of the two echocardiographic criteria was fulfilled. Six families (11%) gave a history of sudden unexplained death in a first degree relative and these were recorded as "possible" cases of dilated cardiomyopathy.
Thus an additional 15 of 56 (27%) showed a "possible" familial tendency to dilated cardiomyopathy. Four families had more than one first degree relative with a definite or possible diagnosis of dilated cardiomyopathy. Therefore the familial occurrence of dilated cardiomyopathy in this patient group was "definite" in 14 (25%) and "possible" in a total of 25 (14 + 11) (45%) of the 56 proband families screened (tables 1 and 2).
HLA DISTRIBUTION
The HLA types in the 100 probands were compared with a reference population of 9000 normal controls from the National Transfusion Service. As compared to these controls, the total group of patients with dilated cardiomyopathy showed no significant differences in halotype. However, when only those dilated cardiomyopathy probands with a familial tendency were evaluated, the DR4 subtype was more common than in the whole patient population or in the controls (68% v 39% v 32%).
There was no significant difference in the proportion of all patients with dilated cardiomyopathy who had the DR4 subtype compared with the general population. However, within the study group, the proportion of patients with familial dilated cardiomyopathy and HLA-DR4 (17 of 25; 68%) was greater than the proportion of patients with non-familial dilated cardiomyopathy and HLA-DR4 (10 of 31; 32%) (P < 0 05, were the first to report a HLA link in patients with dilated cardiomyopathy.3 They found that the HLA types DR4 and B27 were commoner in patients than controls. The halotype frequency of B27 was 14-5% in patients with dilated cardiomyopathy compared with 3-3% in controls, while the frequency of DR4 was 54% in dilated cardiomyopathy and 32% in controls (P = 0-001 and 002, respectively). The HILA-DR4 association with dilated cardiomyopathy has since been confirmed by many other studies'2 17 and refuted by one.'8 The latter was a retrospective look at a particular subset of patients who underwent cardiac transplantation. It is of interest to note that patients undergoing heart transplantation have less cellular rejection and increased long term survival if they are HLA-DR matched with the donor heart.'9 This matching process may be of particular importance in patients with familial dilated cardiomyopathy who are being considered for transplantation.
The search for humoral markers of autoimmunity in patients with dilated cardiomyopathy has been going on for the last 20 years. Natural killer leucocytes are known to be important in host immune surveillance and mediate resistance to viral infections. Natural killer cell deficiency has been shown to be a disease marker for dilated cardiomyopathy, and this subgroup of patients with dilated cardiomyopathy was distinguished from others by an increase in specific HLA halotypes. 20 Relatives of dilated cardiomyopathy patients with the DR4 subtype are at particular risk of developing the disease and should probably be screened regularly by echocardiography, as well as counselled regarding potential lifestyle and pharmacological interventions which might alter the natural history of the disease. Obviously, some relatives with a normal echo at a single screening may later develop dilated cardiomyopathy. Only an ongoing prospective study screening all available first degree relatives on a regular basis would determine the true prevalence of familial dilated cardiomyopathy and the usefulness of markers such HLA typing in identifying those families at greatest risk. When sufficient asymptomatic screen detected relatives with dilated cardiomyopathy are identified, randomised trials of ACE inhibition or immunotherapy to slow disease progression should be initiated.
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